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How can we really improve screening methods for AD prevention trials?John C. S. Breitnera,b,*
aCentre for Studies on Prevention of Alzheimer’s Disease, Douglas Hospital Research Centre, Montreal, Quebec, Canada
bDepartment of Psychiatry, McGill University Faculty of Medicine, Montreal, Quebec, CanadaThis edition of Alzheimer’s & Dementia: Translational
Research & Clinical Interventions includes an important
article from Lutz et al. on the potential advantages of a novel
genetics-based risk algorithm (GRBA) for selection of par-
ticipants in Alzheimer’s disease (AD) prevention trials [1].
The GRBA, described previously [2], has been used to iden-
tify subjects for the well-known TOMMORROW trial of
pioglitazone for prevention of symptomatic AD dementia
or MCI due to AD.
Efficient screening methods are of paramount importance
for AD prevention trials. Studies such as TOMMORROW
require years of follow-up, and they cost scores of millions
of dollars. These costs accrue in part from the screening
methods themselves, but they relate much more strongly to
the trials’ size and the duration of labor-intensive follow-
up needed to identify sufficient “events” for adequate statis-
tical power.
Certainly, the GBRA described here must be among the
lower cost methods of screening. Relying as it does only
on age and genetic markers available from peripheral blood,
it should have clear cost advantages when compared against
more elaborate or invasive screening techniques such as
amyloid-PET scanning or CSF biomarker assays. Not sur-
prisingly, therefore, Lutz et al. compare their GBRA with
some of the latter, more ambitious methods. But the more
salient portion of their argument relates to the comparison
of the GBRAwith similarly low cost and minimally invasive
methods relying on age and peripheral blood markers.
Given that the GRBA is relatively inexpensive per candi-
date screened, how does it perform otherwise? Two factors
determine its efficiency. First is the number of persons
who must be screened to provide the needed number of
“events”. Second is the efficiency of the method in rejecting
persons who will not “convert” from cognitively normal to*Corresponding author. Tel.: 11-514-761-6131, ext. 3940; Fax: 11-
514-221-4700.
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costly, as they must be followed laboriously .5 years for
incident symptoms.
Consideration of test efficiency requires recognition, first,
that only a certain proportion of any population will develop
symptoms. This proportion is commonly referred to as the
base rate of the population. Importantly, it can vary from
one population to another, but it does not depend in any
way on screening results. Whatever the base rate, an impor-
tant function of the screening test is to identify the highest
proportion of those candidates who will become symptom-
atic (the sensitivity of the test). More crucially, however
(see below), the test should minimize the proportion of
false-positives it identifies for trial enrollment. That propor-
tion is, in fact, the complement of the test’s specificity or pro-
portion of “nonconverters” who are identified correctly as
test negative.
Unlike other metrics such as the risk ratio associated with
test positivity, the overall proportion of converters and non-
converters who are correctly identified or the positive and
negative predictive values (PPV, NPV) in the test population,
sensitivity and specificity are performance characteristics of
the test exclusively. All other metrics depend in someway on
the characteristics of the sample being screened. This latter
shortcoming becomes important when comparing the per-
formance of two or more test algorithms across multiple
population samples. An important strength of the Lutz
article is its direct comparison of the sensitivity and speci-
ficity of their GBRA with other algorithms based on age
and APOE ε4 carriage alone, in its Fig. 4.
All screening tests generate two types of error—false-
negatives (resulting from limitations in sensitivity) and
false-positives (reflecting imperfect specificity). A cardinal
principle, to be demonstrated below, is that false-positives
raise trial costs much more than false-negatives. Fig. 1 is
meant to illustrate this point. Panel A shows results obtained
with no screening test except that participants must be old
enough that 10% of them will develop symptoms over the
coming 5 years (i.e., the base rate here, as elsewhere in theimer’s Association. This is an open access article under the CC BY-NC-ND
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Fig. 1. Four hypothetical applications of screening methods when selecting
participants for an AD/MCI prevention trial in a population with base rate of
10% who will develop symptoms over 5 years of follow-up. (A) shows re-
sults with no screening test. (B) represents results expected with a screening
test that provides 60% sensitivity and 60% specificity in identification of
those who will “convert” during the 5-year trial interval. (C) indicates a de-
gree of improvement expected if sensitivity of the prior method can be
improved to 80% with no change in specificity. (D) shows the results ex-
pected when specificity is improved to 80% but sensitivity is 60%, as in
(B). Implications for the costs of the trial are substantial (see text).
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the null hypothesis of no treatment effects, the trial must
observe 500 “events” over 5 years for adequate statistical po-
wer. In panel A, the 10% base rate implies that, without some
method of enrichment, we would need a trial cohort of some
5000 persons. There are no costs for screening (other than
for establishing basic eligibility requirements), but one
may estimate that the all-in costs of the labor-intensive
follow-up of these participants will be $10,000 per year
(probably a conservative figure). Therefore, once eligible
participants have been recruited, the trial will cost
$10,000/participant/year! 5000 participants! 5 years or
$250 million.
To avoid such enormous costs, one can use a screening
test to enrich the trial cohort for those who will become
symptomatic. Panel B shows results expected from a rela-
tively good screening test that achieves sensitivity and spec-
ificity of 60% (i.e., a 40% false-positive rate). The screening
test might cost $1000 per participant screened (an assump-
tion to be used throughout this discussion). The test’s sensi-
tivity of 60% determines that one must screen 833 (500/
60%) individuals to identify the needed 500 “events” in
the trial. But we can identify these persons only after the
fact. Because the 5-year base rate is still 10%, we need to
screen 8333 persons in all to find these 833 “true” converters.
Among the 7500 (8333 2 833) nonconverters to bescreened, however, the false positive rate of 40% means
the trial will identify (and thus enroll) 3000 other persons
who are screen positive. Without knowing it, the trial enrolls
these along with the 500 “true” screen-positives (3500 in all)
and follows them for 5 years. Total screening costs are 8333
! $1000 per screen or $8.3 million. But to follow the cohort
and count outcomes will cost 3500 participants ! $10,000
per participant per year ! 5 years, or $175 million. Total
costs of the trial are therefore $183.3 million, representing
a savings of $66.7 million (27%) compared to panel A.
One can try to improve on this result by increasing either
the sensitivity or the specificity of the screening test. Which
approach holds the potential for greater savings? Panel C
shows results expected when one improves the sensitivity
to 80%, whereas specificity is unchanged at 60%. Because
of the improved sensitivity, one needs now to screen only
625 “true” converters to find the needed 500 trial “events.”
Because the base rate has not changed, one must screen
6250 individuals in all, including not only the 625 but also
5625 nonconverters. Among the 5625 nonconverters
screened, the false-positive rate is still 40%, so the trial
will identify and enroll 2250 false-positives. Total trial
enrollment will therefore be 500 1 2250 5 2750. Costs
for follow-up observations will be 2750 ! $10,000 per
participant per year! 5 years 5 $137.5 million. Screening
costs are 6250! $1000 5 $6.25 million, so total costs will
be $143.75 million. The savings of an additional $40 million
demonstrate clearly that costs can be reduced by screening
methods with improved sensitivity.
But how does this benefit compare with an alternate
method that improves specificity by a nominally identical
amount (to 80%), while holding sensitivity at 60%? Panel
D provides the answer. Once again, the test’s sensitivity of
60% means one must screen 833 “true” converters to find
the trial’s 500 required “events.” The base rate (unchanged)
then implies that one must screen 8333 people in all, of
whom 7500 will be nonconverters. Of the 7500, the new
false-positive rate of 20% means that the trial will now iden-
tify and enroll only 1500 false positives. Total enrollment
will therefore be 1500 1 833 5 2333. Screening costs are
back to $8.3 million, but follow-up costs will now be 2333
! $10,000 ! 5 5 $116.65 million. With total costs of
$125 million, the improved-specificity screener has saved
$58.3 million, or an $18.75 million improvement over the
higher sensitivity method.
The lessons from these examples seem clear enough.
Because the costs of follow-up in AD prevention trials far
exceed the costs of screening, specificity trumps sensitivity
in this application. The advantages of nominally identical
improvements in sensitivity versus specificity are not equal.
One further example makes this point emphatically. The
forthcoming API-Novartis trial of two different anti-amyloid
strategies (NCT02565511) is slated to enroll some 1300 per-
sons, all of whom will be homozygous for the APOE ε4
allele. Stated otherwise, the “screening test” here will be
whether the candidate has genotype ε4/ε4. If yes, the person
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fact, many studies have established that, depending on their
age, APOE ε4 homozygotes are at 10–15-fold higher risk of
incident AD dementia than others in the population [3]. It is
also evident that (depending on age) as many as 60% of them
will develop symptoms over an interval of 5 years (i.e., the
positive-predictive value of the test may be 60%) [4]. But
that does not mean that the sensitivity of APOE ε4/ε4 as a
screening criterion in an AD prevention trial is high.
APOE ε4 homozygotes constitute only 2.3% of most popu-
lations when (depending on age) the trial population will
probably have a base rate similar to the above-assumed
10% who will develop symptoms over the next 5 years.
The sensitivity of this screening test is therefore no more
than 15% (remember, not all test-positive individuals will
develop symptoms; perhaps 40% will become false-
positives.) Importantly, though, the overall false-positive
rate in the test population using the ε4 homozygote
screening criterion is only 1%–2% (principally because
97.7% of the population will be test-negative and therefore
cannot be false-positives).
Applying the API-Novartis screening techniques to the
previous set of assumptions, this trial would need to screen
35,000 persons to identify 800 “screen-positives” who, in
turn might yield the 500 needed “events”. For present pur-
poses, one may again assume that each participant screened
costs $1000. If so, the trial’s screening costs might amount to
$35 million. If one estimates as before that the follow-up
costs for each trial enrollee are $10,000 per year, one can
see that the costs for follow-up of eligible subjects will be
$10,000 per subject-year ! 800 subjects ! 5 years, or
$40 million. Total cost would be this sum plus $35 million
for screening, or $75 million, that is, ,two-thirds that of
the improved-specificity example above.
What can all this tell us about the work of Lutz and
colleagues? These authors, having developed their GBRA
in an ADRC data set, attempted to validate its utility versus
other methods in the well-known Alzheimer’s Disease Neu-
roimaging Initiative (ADNI-1) sample. The GBRA features
a combination of APOE genotype, age, and determination of
allelic isoform of the polymorphic translocase of outer mito-
chondrial membrane 40 homolog (TOMM40) rs10524523
variable length poly-T repeat (TOMM400523). Lutz et al.
compare the utility of the GBRA and other screening algo-
rithms including, notably, a combination of age and APOE
genotype alone. Fig. 3 of their article compares thesensitivity and false-positive rate (1 2 specificity) of the
GBRA with the other screening methods in both the
ADRC and the ADNI cohorts. Notwithstanding their asser-
tion that the GBRA yields impressive PPV and NPV, Fig. 3
is difficult to interpret, as the various screening algorithms
give results that are in very different regions of the receiver
operating characteristic (ROC) curves for the two samples.
ROC analyses are useful for observing the “trade-off” be-
tween sensitivity and specificity achieved by a screening
method as the test cut-off is altered, or as the characteristics
of the population may change. A clearer presentation of the
relative performance of the GBRA in the two samples is
shown in Fig. 4 of the article. Fig. 4A suggests a modest
improvement for the GBRA versus age and APOE alone in
the Bryan ADRC cohort. However, Fig. 4B shows this
same comparison in the validation ADNI cohort. The au-
thors do not analyze the areas under the curve (AUC) for
the two methods (the usual way in which competing
screening algorithms can be compared). It seems unlikely,
however, that there is any meaningful difference in the
AUC for the two curves in Fig 4B.
To this observer, the “bottom line” from all this is that the
paramount criterion for efficiency in prevention trials is
choice of a screening method that emphasizes specificity.
As Fig. 3 of the Lutz article suggests, there is almost invari-
ably a trade-off between sensitivity and specificity as one
modifies a screening test. As the API-Novartis example
shows, in this trade-off concern for specificity should pre-
vail, even if this means accepting a sensitivity that appears
mediocre. As a generalization, this principle appears to
outweigh by far any advantage generated by improved test
technology.
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